Cytrx Corp (NASDAQ:CYTR)

CAPS Rating: 1 out of 5

A biopharmaceutical research and development company engaged in developing human therapeutic products based primarily upon its small molecule molecular chaperone co-induction technology.

Caps

How do you think CYTR will perform against the market?

Add Stock to CAPS Watchlist

All Players

199 Outperform
30 Underperform
 

All-Star Players

22 Outperform
16 Underperform
 

Wall Street

1 Outperform
0 Underperform
 

Top CYTR Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

feenix1944 (< 20)
Submitted June 28, 2014

I've been backing the truck up to buy more CYTR on this recent weakness. I've drilled down pretty deep on the recent Stage IIb trial results and am fully convinced CYTR is a double bagger at the very least, and more likely a triple when the final… More

SmartAce (99.97)
Submitted May 15, 2018

Mail some pirates a treasure map leading to the exact spot where you need a hole dug for a tree.

CYTR VS S&P 500 (SPY)

Fools bullish on CYTR are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about CYTR.

Recs

0
Member Avatar DigitalDisco (92.08) Submitted: 11/1/2017 11:01:35 AM : Underperform Start Price: $2.04 CYTR Score: +66.21

reverse split

Recs

0
Member Avatar superstar2 (99.46) Submitted: 7/12/2016 9:56:31 AM : Outperform Start Price: $4.59 CYTR Score: -111.62

Valuation: considering cash on hand, debt, burn rate, etc. -- above .90 cents. Conservative valuation.

Recs

1
Member Avatar feenix1944 (< 20) Submitted: 6/28/2014 12:34:12 PM : Outperform Start Price: $24.90 CYTR Score: -139.82

I've been backing the truck up to buy more CYTR on this recent weakness. I've drilled down pretty deep on the recent Stage IIb trial results and am fully convinced CYTR is a double bagger at the very least, and more likely a triple when the final results of the global trials are in. The CAPS Community seems to agree wholeheartedly, as well as a number of analysts.
One example from Wall St 24/7:
CytRx Corporation (NASDAQ:CYTR) on May 28 announced updated results from its ongoing multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas (STS). The updated trial results demonstrated that aldoxorubicin significantly increases progression-free survival (PFS), PFS at 6 months, overall response rate (ORR) and tumor shrinkage, compared to doxorubicin, the current standard-of-care, as a first-line treatment in patients with STS. Analysts mean target price for CytRx Corporation (NASDAQ:CYTR) is $11.00 and On Friday shares its shares opened at $4.25 and trading at $4.14.CytRx Corporation (NASDAQ:CYTR) quarterly earnings growth is 134.80%.
Fellow Fools, I rest my case...
Feenix1944

Leaderboard

Find the members with the highest scoring picks in CYTR.

Score Leader

whatsthepoint

whatsthepoint (99.98) Score: +302.81

The Score Leader is the player with the highest score across all their picks in CYTR.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
mansloth 97.73 6/14/2010 Underperform 3Y $34.82 -97.51% +153.75% +251.26 0 Comment
longtermgrowth09 < 20 8/3/2010 Underperform 5Y $40.32 -97.85% +149.33% +247.18 0 Comment
mathan406 73.11 2/8/2008 Underperform 1Y $82.48 -98.95% +118.39% +217.33 0 Comment
trigfish 68.18 8/16/2007 Underperform 3M $123.35 -99.30% +111.19% +210.49 0 Comment
betoo2002 < 20 1/29/2007 Underperform 3M $92.42 -99.06% +109.35% +208.41 0 Comment
tcampbellla 80.44 3/27/2007 Underperform 5Y $173.42 -99.50% +107.58% +207.08 0 Comment
xds68 89.41 2/23/2007 Underperform NS $161.57 -99.46% +104.97% +204.43 0 Comment
ffruga61 62.61 2/22/2007 Underperform 3M $171.95 -99.50% +104.53% +204.03 0 Comment
protozoa1 96.36 2/21/2007 Underperform NS $198.46 -99.56% +104.41% +203.97 0 Comment
jiminica 77.91 2/16/2007 Underperform 1Y $150.23 -99.42% +104.37% +203.80 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackBroadpointAmTech < 20 10/24/2007 Outperform NS $147.65 -90.29% -8.73% -81.56 4/17/2012 @ $14.34 0 Comment
TrackOppenheimer 69.70 10/19/2007 Outperform NS $139.92 -99.38% +91.93% -191.31 0 Comment

Advertisement